Class Colloquium 13: Depression, a discussion with Dr. Jerry Rosenbaum, March 9th at 1:30 pm EST
Editors Note: Classmate Jerry Rosenbaum, MD, served as Chief of Psychiatry at Massachusetts General Hospital for most of the last 20 years, as well as holding a named chair at Harvard Medical School. A recognized leader in research into anxiety and mood disorders, including treatment resistant depression, Dr. Rosenbaum stepped away from his MGH Chairmanship in 2019, transitioning into innovative clinical investigation and further development of psychiatric therapeutics as a co-founder of a promising startups, Psy Therapeutics and Sensorium Therapeutics, and as a Director of MGH’s new Center for the Neuroscience of Psychedelics. See his impressive full bio below.
What IS “Depression” anyway? Not the economic one — the psychological one! And what is actually going on when Depression manifests later in life, in your 70s?
Our guide will be a world-class expert, classmate Jerry Rosenbaum, MD (Saybrook ’69; Yale Med ’73, and 47 years teaching at Harvard Med) who served as former Chief of Psychiatry at Mass General. He’ll share the latest understanding of the mental and associated physical state of clinical depression in septuagenarians like ourselves, and more broadly across all of society.
Jerry has published extensively, on many aspects of psychiatric diagnosis and care. But depression has remained one of his his principal interests. He has played an important role in the development of pharmacological treatments as well as other treatment approaches. He’s presently a Director of the Center for the Neuroscience of Psychedelics at Mass General and co-founder of a company bringing advanced therapeutics for depression (and other CNS conditions). We’ll be in good hands. Great hands, actually.
Join us for our 13th Class Colloquium via Zoom on Wednesday, March 9th at 1:30 PM EST for an interactive session focused upon “Depression.” Jerry will share his expertise, offer his perspective, and discuss current and future approaches and therapeutic options.
Submit your questions when registering, or in the ‘Chat’ during the session. Don’t miss this opportunity to truly expand your understanding.
If you don’t, you’ll certainly be depressed! So, register now and don’t miss out.
Click to register for this meeting:
https://us06web.zoom.us/meeting/register/tZwrc-qrqTguE9fJn3MAszVrFTIFMm_PRHO7
After registering, you will receive a confirmation by email containing information about joining the meeting.
We will start promptly, so please JOIN the meeting 5-10 minutes early.
I hope you can attend. Don’t forget to register and mark your calendars.
Last, if you have any questions for our speaker, you can leave them on this quick-survey form.
BTW, if you haven’t used Zoom yet, Editor Wayne Willis has written a little how-to article to help you get over any technical concerns or questions; and if you need some personal support, he’s happy to call you and walk you through getting set up … for reasons outlined in that article. Just ping him at support@Yale1969.org.
About The Speaker
Until 2019 and for 20 years, Dr. Rosenbaum, Stanley Cobb Professor of Psychiatry at Harvard Medical School, chaired a department of 600 clinicians and researchers, and 150 trainees, ranked by U.S. News and World Report as #1 in the United States in 2019 and for 20 of the prior 24 years, with 60 specialty clinical and research programs and over 70 million dollars of annual research spending.
At MGH, the nation’s largest hospital-based research institution, with over 1 billion dollars of annual research, he served as Chair of the Executive Committee on Research.
As 2007 recipient of the C. Charles Burlingame Award for lifetime achievement in psychiatric research and education, he was 2016 recipient of the Joseph B. Martin Dean’s Leadership Award for the Advancement of Women Faculty for Harvard Medical School.
Emeritus Fellow of the ACNP, he is a 2018 Ellis Island Medal of Honor awardee.
Past President/Board Chair of the Anxiety and Depression Association of America (ADAA), he served as President and is Board member of the American Foundation for Suicide Prevention.
He served a 6 year term as Trustee of the Massachusetts General Hospital and was Trustee of the Partners Healthcare System and is co-Chair of Development at MGH.
Co-author of more than 400 original articles and reviews, and editor of 20 books, he led longitudinal studies of children at risk for anxiety disorders and depression, which examined behavioral differences, risk factors, longitudinal outcomes, treatment, genetics, and brain structure, and function of children of parents with mood and anxiety disorders.
He currently is directing a new MGH center (The Center for Neuroscience of Psychedelics), to understand how psychedelics change the brain and to explore novel mechanisms for treatment of psychiatric disorders.
He co-founded Psy Therapeutics to advance the discovery of novel drugs for psychiatric and neurologic disorders (www.psythx.com) and is co-founder of Sensorium Therapeutics, Inc. to explore plant derived molecules as leads for novel psychiatric therapeutics.
He graduated in 1969 from Yale College (American Studies) and 1973 from Yale Medical School and trained in Psychiatry at Massachusetts General Hospital, Harvard Medical School.